Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks

August 27, 2014
Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks

Ebola is a rare, but deadly disease that exists as five strains, none of which have approved therapies. One of the most lethal strains is the Sudan ebolavirus (SUDV). Although not the strain currently devastating West Africa, SUDV has caused widespread illness, even as recently as 2012. In a new study appearing in the journal ACS Chemical Biology, researchers now report a possible therapy that could someday help treat patients infected with SUDV.

John Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that about 50-90 percent of ebola patients die after experiencing the typical symptoms of the disease, which include fever, muscle aches, vomiting and bleeding. Of the five known ebolaviruses, the Zaire (EBOV) and SUDV are the most deadly and cause the most recurring outbreaks. Many studies have focused on EBOV, the culprit of the current epidemic, but much less attention has been placed on SUDV until now. To develop a therapy for SUDV, this research team turned to an antibody that Dye's group previously reported.

The team's antibody was directed against SUDV and was made in mice. But the human immune system could potentially recognize that antibody as foreign and ultimately get rid of it, preventing the antibody from treating the disease. To avoid this situation, they wanted to make a "humanized" version of the antibody.

In the newly published work, the team put the ebola-specific part of the mouse antibody onto a scaffold and made some changes to this molecule. They identified two versions that were able to fend off SUDV in laboratory tests on cells and in specially bred mice. "These antibodies represent strong immunotherapeutic candidates for the treatment of SUDV infection," say the researchers.

This research, however, isn't expected to help with the current that, as of mid-August, has killed at least 1,200 people. That's because antibodies that kill off one strain of the virus haven't worked against other strains. The U.S. Food and Drug Administration—which has not yet approved any ebola therapies—did allow two U.S. aid workers infected during the current outbreak to be treated with an experimental drug, which is a cocktail of specifically targeting EBOV.

More information: "Synthetic Antibodies with a Human Framework that Protect Mice from Lethal Sudan Ebolavirus Challenge" ACS Chem. Biol., Article ASAP
DOI: 10.1021/cb5006454

Related Stories

Recommended for you

Organic semiconductors get weird at the edge

October 6, 2015

As the push for tinier and faster electronics continues, a new finding by scientists at the University of British Columbia (UBC) and Monash University could help inform the design of the next generation of cheaper, more efficient ...

New polymer creates safer fuels

October 1, 2015

Before embarking on a transcontinental journey, jet airplanes fill up with tens of thousands of gallons of fuel. In the event of a crash, such large quantities of fuel increase the severity of an explosion upon impact. Researchers ...

Researchers print inside gels to create unique shapes

September 30, 2015

(Phys.org)—A team of researchers at the University of Florida has taken the technique of printing objects inside of a gel a step further by using a highly shear-rate sensitive gel. In their paper published in the journal ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.